Common Contracts
11 similar Letter Agreement contracts by Diffusion Pharmaceuticals Inc., Arcadia Biosciences, Inc., Can-Fite BioPharma Ltd., others
STRICTLY CONFIDENTIAL Diffusion Pharmaceuticals Inc.Letter Agreement • May 20th, 2020 • Diffusion Pharmaceuticals Inc. • Pharmaceutical preparations • New York
STRICTLY CONFIDENTIAL Diffusion Pharmaceuticals Inc.Letter Agreement • December 13th, 2019 • Diffusion Pharmaceuticals Inc. • Pharmaceutical preparations • New York
STRICTLY CONFIDENTIAL Diffusion Pharmaceuticals Inc.Letter Agreement • November 8th, 2019 • Diffusion Pharmaceuticals Inc. • Pharmaceutical preparations • New York
STRICTLY CONFIDENTIAL Arcadia Biosciences, Inc.Letter Agreement • September 9th, 2019 • Arcadia Biosciences, Inc. • Agricultural chemicals • New York
STRICTLY CONFIDENTIAL Diffusion Pharmaceuticals Inc.Letter Agreement • May 28th, 2019 • Diffusion Pharmaceuticals Inc. • Pharmaceutical preparations • New York
STRICTLY CONFIDENTIAL Intellipharmaceutics International Inc.Letter Agreement • March 16th, 2018 • Intellipharmaceutics International Inc. • Pharmaceutical preparations • New York
STRICTLY CONFIDENTIAL Jeffrey Bacha Chairman & CEO DelMar Pharmaceuticals, Inc. Suite 720 - 999 West Broadway Vancouver, British Columbia Canada V5Z 1K5 Dear Mr. Bacha:Letter Agreement • April 13th, 2017 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This letter agreement (this “Agreement”) constitutes the agreement between DelMar Pharmaceuticals, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”) that Wainwright shall serve as the exclusive agent, advisor or underwriter in an offering (the “Offering”) of securities of the Company (“Securities”) during the Term (as defined below) of this Agreement. The terms of the Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Wainwright’s assistance in the Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and to the receipt of all internal approvals of Wainwright in connectio
March 9, 2016Letter Agreement • March 10th, 2016 • International Stem Cell CORP • Pharmaceutical preparations • New York
STRICTLY CONFIDENTIAL Geert Cauwenbergh, Dr. Med. Sc. President and Chief Executive Officer RXi Pharmaceuticals CorporationLetter Agreement • May 21st, 2015 • RXi Pharmaceuticals Corp • Pharmaceutical preparations • New York
STRICTLY CONFIDENTIALLetter Agreement • December 4th, 2014 • Can-Fite BioPharma Ltd. • Pharmaceutical preparations • New York
H.C. Wainwright Letterhead] June 13, 2014Letter Agreement • August 19th, 2014 • Mela Sciences, Inc. /Ny • Surgical & medical instruments & apparatus • New York
